BRAFi have been shown to exert immunomodulatory effects, such as upregulation of melanoma antigens in vitro 24, increased T‐cell infiltration in tumors 25, reversed immunosuppression by myeloid‐derived suppressor cells 26 and enhanced PD‐L1 expression 8. The gene discussed is CD274; the disease is melanoma.